Journal rankings · indicator year 2022
Choose a field to open its ranking, or a journal to find its row in its subfield’s list.
Field ranking · 2022
Biochemistry, Genetics and Molecular Biology journal rankings 2022
1,358 ranked journals · Field in Life Sciences
Biochemistry, Genetics and Molecular Biology has 1,358 ranked journals in 2022. The median journal has an OJR of 0.89, below the world average of 1.00, down 0.01 on 2021; Q1 starts at OJR 1.35. The top three are Cell, Molecular Cancer, and Nature Genetics.
Ranks and citation indicators: 2022. Journal access status and listed APC: source snapshot September 23, 2026.
Journals whose main subfield sits in this category and that published at least 30 citable documents (articles, reviews and conference papers) in 2019–2021, the window the 2022 score is computed on.
The OpenJournalRank Indicator (OJR) is a free, publicly available metric of a journal’s field-normalized citation impact, computed from open OpenAlex citation data. It compares citations to a journal’s papers from the previous three years with the world average for papers of the same subfield, year and type, so 1.00 is the world average and values can be compared across fields. It is computed with the NCI3 method.
The middle OJR among ranked journals in this category: half score higher, half lower. 1.00 is the world average for papers of the same subfield, year and type.
The dot is this category, the solid tick is the median of all ranked journals and the dashed line is the world average.
Share of ranked journals in this category that are fully open access, so every paper is free to read. Hybrid journals, which sell subscriptions and open single papers for a fee, are not counted.
Median list price of the article processing charge, in US dollars, among ranked journals in this category that list a price above zero. Journals with a listed APC of $0 and journals with no known price are left out of this median. The At a glance table below gives a second median that includes the $0 prices.
Subfields in Biochemistry, Genetics and Molecular Biology (14)
Up to Life Sciences1,358 ranked journals
Filters
Rank is the position by OJR within the list on screen; 1 is the highest. | OJR is field-normalized 3-year citation impact: 1.00 is the world average for papers of the same subfield, year and type, so values compare across fields. The badge is the journal’s quartile in this list. | Citations per paper over a two-year window, counted from OpenAlex. It is not field-normalized, so compare it only between journals of the same field. ▲ or ▼ is the change from 2021. This is OpenJournalRank’s own count, not Clarivate’s Journal Impact Factor. | Citable documents (articles, reviews and conference papers) published in 2019–2021, the window the 2022 OJR is computed on. A journal needs at least 30 to be ranked. | Share of the journal’s 2019–2021 papers that are free to read in any open-access form. The green OA tag next to a title marks a fully open-access journal. | List price of the article processing charge in US dollars. “$0 listed” means the listed price is zero; a dash means no price is listed. | The line is the journal’s OJR from 2013 to 2022. | Compare |
|---|---|---|---|---|---|---|---|
1CellCell Press · United States | 11.19Q1 | 51.75 3.22 down from 2021 | 1,651 | 100% | $11,400 | ||
2Molecular CancerOABioMed Central · United Kingdom | 8.79Q1 | 35.28 7.37 down from 2021 | 478 | 100% | $5,090 | ||
3Nature GeneticsNature Portfolio · United States | 8.64Q1 | 26.89 7.85 down from 2021 | 563 | 68% | $12,690 | ||
4Nature BiotechnologyNature Portfolio · United States | 8.25Q1 | 25.90 10.04 down from 2021 | 837 | 40% | $12,690 | ||
5Current Protocols in BioinformaticsWiley · United States | 7.98Q1 | 46.00 16.15 up from 2021 | 34 | — | $5,050 | ||
6NatureNature Portfolio · United Kingdom | 7.77Q1 | 26.89 0.65 up from 2021 | 8,562 | 37% | $12,690 | ||
7Fungal DiversitySpringer Science+Business Media · Netherlands | 7.11Q1 | 19.81 6.45 down from 2021 | 64 | 72% | $3,490 | ||
8Nature Reviews Molecular Cell BiologyNature Portfolio · United Kingdom | 6.75Q1 | 48.00 0.29 up from 2021 | 326 | 37% | — | ||
9Pharmacological ReviewsAmerican Society for Pharmacology and Experimental Therapeutics · United States | 6.22Q1 | 23.70 0.39 up from 2021 | 84 | 81% | $4,500 | ||
10Cell MetabolismCell Press · United States | 6.22Q1 | 21.31 2.15 down from 2021 | 636 | 100% | $10,400 | ||
11Nature MethodsNature Portfolio · United States | 5.94Q1 | 23.67 1.23 up from 2021 | 964 | 53% | $12,690 | ||
12International Journal of Oral ScienceOASpringer Nature · China | 5.62Q1 | 20.91 16.47 down from 2021 | 114 | 100% | $3,890 | ||
13Nature MicrobiologyNature Portfolio · United Kingdom | 5.51Q1 | 25.18 2.08 down from 2021 | 637 | 67% | $12,690 | ||
14Nature reviews. CancerNature Portfolio · United Kingdom | 5.21Q1 | 39.93 7.28 up from 2021 | 318 | 30% | — | ||
15Nature Ecology & EvolutionNature Portfolio · United Kingdom | 5.12Q1 | 12.94 1.79 down from 2021 | 775 | 47% | $12,690 | ||
16Drug Resistance UpdatesElsevier BV · United Kingdom | 5.03Q1 | 25.00 0.22 up from 2021 | 66 | 48% | $5,410 | ||
17Nature Biomedical EngineeringNature Portfolio · United Kingdom | 5.03Q1 | 20.62 2.46 up from 2021 | 445 | 60% | $12,690 | ||
18Circulation ResearchLippincott Williams & Wilkins · United States | 4.96Q1 | 17.94 1.05 up from 2021 | 778 | 36% | — | ||
19MicrobiomeOABioMed Central · United Kingdom | 4.95Q1 | 17.42 2.30 down from 2021 | 538 | 100% | $4,990 | ||
20Signal Transduction and Targeted TherapyOASpringer Nature · United Kingdom | 4.84Q1 | 22.57 0.53 down from 2021 | 783 | 100% | $3,790 | ||
21Nature CommunicationsOANature Portfolio · United Kingdom | 4.74Q1 | 18.23 1.70 down from 2021 | 18,537 | 100% | $6,990 | ||
22Cell Host & MicrobeCell Press · United States | 4.64Q1 | 22.53 1.61 down from 2021 | 605 | 100% | $10,400 | ||
23Nature Reviews Drug DiscoveryNature Portfolio · United States | 4.63Q1 | 25.41 2.94 up from 2021 | 550 | 14% | — | ||
24The InnovationOAElsevier BV · United States | 4.57Q1 | 19.62 2.11 up from 2021 | 172 | 100% | $5,000 | ||
25Cell ResearchSpringer Nature · United Kingdom | 4.54Q1 | 23.26 0.86 down from 2021 | 444 | 100% | $5,190 | ||
26Nature ProtocolsNature Portfolio · United States | 4.48Q1 | 16.19 2.28 down from 2021 | 520 | 54% | — | ||
27Nature Reviews MicrobiologyNature Portfolio · United Kingdom | 4.44Q1 | 31.22 5.71 up from 2021 | 520 | 39% | — | ||
28Nature MetabolismNature Portfolio · United Kingdom | 4.38Q1 | 16.51 2.18 up from 2021 | 434 | 57% | $12,690 | ||
29Nature Cell BiologyNature Portfolio · United Kingdom | 4.33Q1 | 15.58 2.87 down from 2021 | 482 | 61% | $12,690 | ||
30Science AdvancesOAAmerican Association for the Advancement of Science · United States | 4.32Q1 | 15.00 1.60 down from 2021 | 5,392 | 100% | $4,500 | ||
31ScienceAmerican Association for the Advancement of Science · United States | 4.27Q1 | 16.01 0.68 up from 2021 | 10,232 | 32% | — | ||
32Cell stem cellElsevier BV · United States | 4.16Q1 | 16.45 0.36 down from 2021 | 589 | 100% | $10,400 | ||
33Genome biologyOABioMed Central · United Kingdom | 4.14Q1 | 13.21 6.39 down from 2021 | 913 | 100% | $5,490 | ||
34Bone ResearchOASpringer Nature · China | 4.09Q1 | 13.44 1.10 down from 2021 | 120 | 100% | $3,405 | ||
35Military Medical ResearchOABioMed Central · China | 4.09Q1 | 18.23 8.62 down from 2021 | 161 | 100% | $0 listed | ||
36Physiological ReviewsAmerican Physiological Society · United States | 4.06Q1 | 29.09 9.57 down from 2021 | 128 | 78% | — | ||
37ACS Central ScienceOAAmerican Chemical Society · United States | 3.90Q1 | 17.96 0.18 up from 2021 | 587 | 100% | $0 listed | ||
38Biotechnology AdvancesElsevier BV · United Kingdom | 3.83Q1 | 14.82 1.57 down from 2021 | 389 | 40% | $5,460 | ||
39Nature AgingNature Portfolio · United States | 3.80Q1 | 11.07 4.93 down from 2021 | 144 | 53% | $12,690 | ||
40Progress in Lipid ResearchElsevier BV · United Kingdom | 3.78Q1 | 15.13 3.11 up from 2021 | 95 | 55% | $5,530 | ||
41Science Translational MedicineAmerican Association for the Advancement of Science · United States | 3.77Q1 | 14.77 0.74 up from 2021 | 1,257 | 67% | — | ||
42Medicinal Research ReviewsWiley · United States | 3.71Q1 | 13.72 0.66 up from 2021 | 241 | 28% | $4,980 | ||
43Nature Reviews GeneticsNature Portfolio · United Kingdom | 3.61Q1 | 19.25 10.55 down from 2021 | 331 | 30% | — | ||
44Nucleic Acids ResearchOAOxford University Press · United Kingdom | 3.60Q1 | 15.06 0.48 up from 2021 | 3,797 | 100% | $3,992 | ||
45MycosphereOAGuizhou Academy of Agricultural Sciences | 3.60Q1 | 14.11 1.06 down from 2021 | 60 | 100% | — | ||
46Journal of Extracellular VesiclesOATaylor & Francis · United States | 3.57Q1 | 16.10 0.08 down from 2021 | 300 | 100% | $4,410 | ||
47Genome MedicineOABioMed Central · United Kingdom | 3.57Q1 | 13.19 2.12 down from 2021 | 380 | 100% | $5,290 | ||
48Experimental & Molecular MedicineOASpringer Nature · South Korea | 3.55Q1 | 14.50 0.93 down from 2021 | 495 | 100% | $4,490 | ||
49Pharmacology & TherapeuticsElsevier BV · United States | 3.55Q1 | 12.43 0.22 up from 2021 | 510 | 45% | $5,660 | ||
50Journal of Clinical InvestigationOAAmerican Society for Clinical Investigation · United States | 3.53Q1 | 13.05 2.47 down from 2021 | 1,748 | 100% | $5,200 |
Subfields of Biochemistry, Genetics and Molecular Biology, compared.
- Molecular Biology1,158
- Genetics120
- Cancer Research27
- Cell Biology26
- Molecular Medicine9
- Biophysics7
- Clinical Biochemistry4
- Biochemistry2
- Structural Biology2
- Developmental Biology1
- Endocrinology1
- Physiology1
- Aging0
- Biotechnology0
Journals
Citations made in 2022. Corpus-wide, 89.5% of core-journal articles and reviews published that year have at least one matched reference; the share varies by journal and field.
430 additional Biochemistry, Genetics and Molecular Biology journals with metrics are unranked under this release’s eligibility rules: a journal needs at least 30 citable documents in 2019–2021, at least 80% of them with a subfield, and a positive world-average expectation. Ranks are within the whole category; filters hide rows without re-ranking. OJR excludes self-citations.
At a glance
Indicator year: 2022. Publication window: 2019–2021. How these summaries are calculated
- Ranked journals
- 1,358
- Window papers (baseline)
- 750,552 +10.5% from indicator year 2019
- Median OJR
- 0.890 -2.6% from indicator year 2019
- Rising journals (2025)
- 141Comparison-group list (141)
Window papers are the baseline paper population: citable papers (articles, reviews and conference papers) from 2019–2021 in all journals of the world-average baseline, including non-core journals, counted by each paper’s own subfield. They are not the papers of the ranked journals alone.
| Measure | Year series | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ranked journals | 609 | 650 | 696 | 742 | 765 | 806 | 835 | 888 | 919 | 951 | 1,003 | 1,064 | 1,125 | 1,172 | 1,217 | 1,271 | 1,311 | 1,339 | 1,365 | 1,369 | 1,349 | 1,339 | 1,358 | 1,366 | 1,355 | 1,367 | |
| Window papers (baseline) | 310,927 | 335,262 | 354,210 | 375,343 | 388,415 | 415,247 | 441,606 | 472,036 | 497,712 | 532,780 | 565,943 | 595,190 | 615,359 | 631,115 | 652,778 | 672,042 | 683,714 | 684,441 | 678,826 | 679,352 | 690,127 | 717,801 | 750,552 | 768,440 | 764,327 | 768,613 | |
| Median OJR | 0.628 | 0.634 | 0.68 | 0.76 | 0.81 | 0.8465 | 0.872 | 0.894 | 0.921 | 0.95 | 0.98 | 1.03 | 1.02 | 0.990 | 0.986 | 0.97 | 0.96 | 0.93 | 0.925 | 0.915 | 0.912 | 0.90 | 0.890 | 0.8474 | 0.853 | 0.871 |
| Measure | Category statistic | Eligible population |
|---|---|---|
| Journal self-citation share | Median: 1.9% | 1,206 journals |
| Retracted papers per 1,000 | Pooled rate: 4.798 per 1,000 | 1,059 journals |
| Output growth | Median: -6.4% | 1,233 journals |
| Open access share | Median: 100.0% | 1,367 journals |
| Listed APC (USD) | Median including $0 listed prices: $3,300 | 943 ranked journals with a known listed price, including $0 listed prices |
| International collaboration share | Median: 24.4% | 1,335 journals |
| Review share | Median: 0.3% | 1,367 journals |
| Articles-only OJR | Median: 0.87 | 1,336 journals |
| Uncited share | Median: 22.7% | 1,367 journals |
| Citation concentration | Median: 42.1% | 1,363 journals |
How to read these rankings
- OJR, the OpenJournalRank Indicator
- A field-normalized 3-year citation impact, computed from OpenAlex with the NCI3 method. It divides the citations a journal’s papers received by the world average for papers of the same subfield, year and type, so 1.00 is the world average and 2.00 means twice as many citations as expected. Because it is normalized, it can be compared across fields. Read the methodology
- Quartiles
- Q1 to Q4 split the ranked journals of the list you are viewing into four equal groups by OJR. A journal’s quartile depends on the list: the same journal can be Q1 in its subfield and Q2 among all journals.
- Impact factor (2-year)
- Citations per paper over a two-year window, counted from OpenAlex. It is easy to compare with familiar impact factors but is not field-normalized, so compare it only within a field. It is not Clarivate’s Journal Impact Factor. Why it differs from the Journal Impact Factor
- Rank ranges
- Each rank in the latest year carries a likely range from 1,000 resamples of the journal’s papers. Where two journals’ ranges overlap, the data cannot tell them apart, so treat neighbouring ranks as ties.